The Federal Trade Commission needs to monitor recent actions by Big Pharma, particularly regarding semaglutide, a key ingredient in diabetes and obesity medications. Companies like Novo Nordisk and Lilly dominate the GLP-1 market, controlling nearly 100% of supply. In 2023, Ozempic generated approximately $13.9 billion in sales, with Novo Nordisk reporting significant increases in diabetes and obesity care sales. The dependence on these two companies raises concerns about market stability, as their decisions can profoundly affect pricing and availability of essential drugs for American patients.
The Federal Trade Commission must monitor Big Pharma's actions concerning necessary medicines, particularly in light of semaglutide's role in diabetes and obesity treatment.
Large pharmaceutical companies are capitalizing on America's diabetes and obesity crises, significantly enhancing their profits with drugs like Ozempic and Wegovy.
The GLP-1 market is heavily dominated by Lilly and Novo Nordisk, which raises concerns about reliance on just two manufacturers for essential medications.
Exclusive dealings and pricing strategies from these dominating firms can significantly impact both consumers and competitors within the pharmaceutical marketplace.
Collection
[
|
...
]